º»¹® ¹Ù·Î°¡±â

·Î±×ÀÎ ¹Ù·Î°¡±â


  • 2026 °øÃ¤

Çѱ¹¼¼¸£ºñ¿¡ ±â¾÷Á¤º¸

Çѱ¹¼¼¸£ºñ¿¡

°ü½É±â¾÷ Ãß°¡Çϰí ä¿ë¼Ò½Ä ¹Þ±â

  • »ç¾÷³»¿ë : ÀǾàǰ
  • ´ëÇ¥ÀÚÇÁ¶û½º±¹ÀÎ ¿Ã¸®ºñ¿¡Çʸ³·ç½î
  • ¼³¸³ÀÏ1990³â 12¿ù 17ÀÏ
  • ¸ÅÃâ¾× 555¾ï 5,564¸¸¿ø (2025)
  • »ç¿ø¼ö 75 ¸í ÀçÁ÷Áß
  • Æò±Õ¿¬ºÀ8,276¸¸¿ø
  • ÀÚº»±Ý 13¾ï 1,800¸¸¿ø

ȸ»ç¼Ò°³

    ȸ»ç¼Ò°³
* ȸ»ç¼Ò°³
SERVIER KOREA is a subsidiary of the European company Servier, one of the leading multinational pharmaceutical companies. With a strong international presence in over 150 countries and a turnover of 5.3 billion euros in 2022-23, SERVIER employ 21,900 people worldwide.
Entirely independent, we reinvest over 20% of our turnover (excluding generic drugs) in research and development and use all our profits for development.
Corporate growth is driven by our constant search for innovation in 4 therapeutic areas
Oncology, Cardiometabolism, Neuroscienceand Immuno-inflammationas, well as by our activities in high-quality generic drugs.
At SERVIER, we are proud to leverage the talent and engagement of our global team to make a meaningful difference in patients' lives.

º¹¸®ÈÄ»ý

  • ÈÞ¹«/±â³äÀÏÁÖ5Àϱٹ«,¿¬Â÷,¿ùÂ÷,º¸°ÇÈÞ°¡,°æÁ¶ÈÞ°¡,⸳ÀÏÈÞ¹«,¹ÝÂ÷,À°¾ÆÈÞÁ÷,»êÀü/ÈÄ ÈÞ°¡
  • 4´ëº¸Çè±¹¹Î¿¬±Ý,ÀǷẸÇè,»êÀ纸Çè,°í¿ëº¸Çè
  • ±³À°/¿©°¡Áö¿øÀÚ±â°è¹ßÁö¿ø,»ç³»µ¿È£È¸
  • º¸Àå/º¸»óÀμ¾Æ¼ºê,Àå±â±Ù¼ÓÆ÷»ó,ÅðÁ÷±Ý,¸íÀý¼±¹°,°æÁ¶»ç Áö¿ø
  • ±Ù¹«È¯°æ/ÆíÀǽĴë,Á÷¿ø´ëÃâ,±³Åëºñ,ÁÖÅÃÀÚ±Ý,À¯Ä¡¿øÇÐÀÚ±ÝÁö¿ø,ÁßµîÇÐÀÚ±ÝÁö¿ø,°íµîÇÐÀÚ±ÝÁö¿ø,´ëÇÐÇÐÀÚ±ÝÁö¿ø,°Ç°­°ËÁø
  • ±âŸÀÓÁ÷¿ø´Üüº¸Çè, ¿µ¾î/ºÒ¾î ±³À°ºñ Áö¿ø, ÁÖÅÃÀÚ±Ý ´ëÃâ, ÁÖÂ÷ºñ Áö¿ø, ÇÚµåÆù ºñ¿ë Áö¿ø, °Ç°­°ËÁø µî

±â¾÷À§Ä¡

  • ÁÖ¼Ò : ¼­¿ïƯº°½Ã ¿µµîÆ÷±¸ ¿©ÀÇ´ë·Î 24 (¿©Àǵµµ¿,¿¡ÇÁÄÉÀ̾ÆÀÌŸ¿ö) 23Ãþ
  • ȨÆäÀÌÁö : http://www.servier.co.kr

µ¿ÀÏ ±â¾÷ÀÌ¶óµµ Å¸Áö¿ª ä¿ëÀÇ °æ¿ì, ȸ»ç ÁÖ¼Ò¿Í Àα٠ÁöÇÏö Á¤º¸°¡ »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.